Results 191 to 200 of about 160,542 (279)

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

Acta Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune‐related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI‐associated DED and to evaluate factors contributing to variability across studies.
Kai‐Yang Chen, Hoi‐Chun Chan, Chi‐Ming Chan   +2 more
wiley   +1 more source

Durable remission of metastatic myxoid liposarcoma following the cautious addition of pembrolizumab to ongoing pazopanib treatment: A case report. [PDF]

Rare Tumors
Abbas H, Samlowski W, Hedayat A.
europepmc   +1 more source

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

Complete remission of small cell neuroendocrine carcinoma of the cervix treated with chemotherapy of paclitaxel, carboplatin, bevacizumab and pembrolizumab: A case report. [PDF]

Gynecol Oncol Rep
Kakubari R, Nonokawa Y, Morita Y, Hosokawa M, Ogimoto K, Yamabe E, Kitai M.   +6 more
europepmc   +1 more source

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta‐analysis

BJU International, EarlyView.
Objective To evaluate the concordance between clinical complete response (cCR) and pathological complete response (pCR) in muscle‐invasive bladder cancer (MIBC) to assess the surrogacy and prognostic value of cCR for guiding bladder‐sparing strategies.
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Alessandro Dematteis, Keiichiro Miyajima, Shota Inoue, Katharina Oberneder, Markus von Deimling, Victor M. Schuettfort, Malte W. Vetterlein, Bernadett Szabados, Pawel Rajwa, Pierre I. Karakiewicz, Jeremy Yuen‐Chun Teoh, Margit Fisch, Shahrokh F. Shariat   +15 more
wiley   +1 more source

Correction: Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors. [PDF]

Front Immunol
Alsaafeen BH, Ali BR, Elkord E.
europepmc   +1 more source

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, EarlyView.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.

JAMA Oncol
Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva FA, Alatorre-Alexander J, Meng R, Amin R, Matheny C, Troutman S, Wen X, Patil NS, Zou W, Rodriguez-Abreu D.   +20 more
europepmc   +1 more source

Pseudo-Progression Observed During Immune Checkpoint Inhibitor Therapy for Advanced Adrenocortical Carcinoma. [PDF]

IJU Case Rep
Shimoda M, Ohtake S, Aoki T, Karibe J, Shibata Y, Imano M, Inoue M, Kobayashi K.   +7 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source